High-throughput microfluidic technology for developing small 3D tissues**

传统的基于细胞的分析提供了在二维(2D)培养系统中研究细胞-细胞、细胞-组织以及细胞-药物相互作用的机会。这些分析被广泛用于筛选调节组织中一系列生物事件中的特定靶点的分子库。然而，使用传统2D模型的表型细胞筛选的成本对于许多大规模分子筛选的公司来说是令人望而却步的。此外，现有的3D组织模型仍然不能概括真实3D组织的基本要求，例如在受控灌流系统下细胞与3D基质的相互作用。在这个项目中，我们将开发一种新的技术来生成更小的逼真3D组织，用于制造有效的生物分子，用于细胞工程或组织治疗。这种技术使得能够制造更逼真的细胞-细胞、细胞-组织、细胞-生物分子相互作用的组织，并有助于在高通量系统中使小组织与非常少量的生物分子相互作用。这种3D组织模型将大大降低测试生物分子性能的成本，使大规模筛选目标分子变得负担得起。这项工作还将消除小组织之间交叉污染的挑战，这是所有现有3D组织分析中的一个关键挑战。这些3D组织模型将有利于SV ChemBiotech开发具有成本效益的组织模型，并大大降低测试生物分子性能的成本，通过使目标分子的大规模筛选变得负担得起，为该公司提供进入一个新市场的机会。*

Conventional cell-based assays offer the opportunity to investigate cell-cell, cell-tissue, and cell-drug interactions in two-dimensional (2D) culture systems. These assays are used extensively to perform screening a library of molecules that modulate a certain target among a broad range of biological events in tissues. However, the cost of phenotypic cell-based screening using conventional 2D models is prohibitive for many companies for large-scale screening of molecules. Also, the existing 3D tissue models do not still recapitulate basic requirements of a real 3D tissue such as the interaction of cells with the 3D matrix under controlled perfusion system. In this project, we will develop a new technology for generating realistic 3D tissues with much smaller size, useful to make effective biomolecules for engineering of cells or treatment of tissues. Such technology enables making more realistic tissues with mimetic cell-cell, cell-tissue, and cell-biomolecules interactions, and helps to make small tissues interacting with a very small volume of biomolecules in a high-throughput system. This 3D tissue model will drastically reduce the cost of testing biomolecules performance, making the large-scale screening of target molecules affordable. This work will also eliminate the challenge of cross-contamination among small tissues, something that is a critical challenge in all existing 3D tissue assays. These 3D tissue models will benefit SV ChemBiotech in developing cost-effective tissue models and drastically reducing the cost of testing biomolecules performance, providing the access to a new market for the company via making the large-scale screening of target molecules affordable.****